Motatmota...thanks for the comments. NLVO adds to the revenue immediately. If they can delivery on the volumes they expect, 300million in revenue is ridiculous in year one. Even if they can do, 230million, then their revenue is equal to their current market cap.
If you look at some of the big players out there, FONE is right there on many fronts, except market cap. Estimates for a couple of the other big players for 2019 revenue:
from Reuters.com
WEED consensus revenue # Mean High Low
| Year Ending Mar-19 | 7 | 354.94 | 522.00 | 255.50 |
Using the Mean estimate, Market Cap 14.1 Billion / 354 million mean estimate :
39X TLRY consensus revenue # Mean High Low
| Year Ending Dec-19 | 5 | 139.02 | 161.30 | 73.43 |
Using the Mean estimate, Market Cap 13.0 Billion / 139.02 million mean estimate :
93X ACB consensus revenue # Mean High Low
| Year Ending Jun-19 | 3 | 407.77 | 419.43 | 398.37 |
Using the Mean estimate, Market Cap 12.2 Billion / 407.77 million mean estimate :
30X I recognize that all three of these companies are ahead of FONE, but at 200-300 million in revenue be Dec 31/19, this is in the range of WEED, TLRY, and ACB. So, we are at 1X revenue vs 30-90X revenue. Pretty easy to do the math. I was happy to be able to buy this under $2, I think I should be happy to buy it under $20.
Also, to note each of WEED, TLRY, ACB have a negative earnings per share estimate as well, until they move into 2020. I cant compare all the opportunites of each of the 3 companies, just looking at Market Cap vs Revenue and see we could potentially be priced multiples higher from here.
Once FONE can start producing at the levels expected, and they are known out there, the price could move very fast if you start comparing it to the bigger players out there.